Bristol-Myers checks off another milestone on the Celgene CVR, hustling Yescarta rival to the market
As Bristol-Myers Squibb wrapped its $74 billion acquisition of Celgene last November, investors began a 16-month countdown to March 2021 — the deadline for the pharma giant to gain approval on three of its new pipeline favorites in order for the $9 contingent value rights to materialize.
Another one of them is now firmly on track to hit the goal early.
The FDA has accepted Bristol-Myers’ BLA for liso-cel, the CD19-directed CAR-T originally developed by Juno, and granted a priority review that brings the PDUFA date up to August 17, 2020.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
